Table 1 KRAS status as a prognostic marker in lung cancer
From: KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target
Reference | Type of study | Patients tested for KRAS | Patients by KRAS status | Results (KRAS-mut vs KRAS-wt) | |
|---|---|---|---|---|---|
KRAS-mut | KRAS-wt | ||||
Mascaux et al., 2005 [61] | Pooled analysis | 3620 (stage I-IV) | 652 | 2968 | HR for OS 1.35 (1.16–1.56), p = 0.01 |
Sheperd et al., 2013 [62] | Pooled analysis | 1543 (stage I-III) | 300 | 1246 | HR for OS 1.17, 95% CI 0.96 to 1.42, p = 0.12 |
Zer et al., 2016 [63] | Pooled analysis | 577 (stage IIIB-IV) | 120 | 457 | HR for OS 1.09, 95% CI 0.85–1.41, p = 0.48 |
Pan et al., 2016 [64] | Pooled analysis | 13,103 (stage I-IV) | 2374 | 10,729 | HR for OS 1.56, 95% CI 1.39–1.76, p = 0.00 |
Svaton et al., 2016 [66] | Individual study | 129 (stage IIIB-IV) | 39 | 90 | OS: 16.1Â months for wt-KRAS and 7.2 for mut-KRAS |
PFS: 2.3 for wt-KRAS and 1.6 for mut-KRAS | |||||
Fan et al., 2017 [65] | Pooled analysis | 658 (advanced NSCLC) | 93 | 565 | HR for PFS 1.83, 95% CI 1.40–2.40, p < 0.0001 |
693 (advanced NSCLC) | 106 | 587 | HR for OS 2.07, 95% CI 1.54–2.78, p < 0.0001 | ||